SWOG clinical trial number
S1801

A Phase II Randomized Study of Adjuvant versus Neoadjuvant Pembrolizumab for Clinically Detectable Stage III-IV High-risk Melanoma.

Open
Phase
II
Accrual
10%
Abbreviated Title
Ph II Ramdomization for Clinically Detectable Stage III-IV High-risk Melanoma
Status Notes
Activation Effective 12/06/2018.
Activated
12/06/2018

Research committees

Melanoma

Treatment

MK-3475

Reports & Approvals

Trial Locations

Other Clinical Trials

SWOG Clinical Trial Number
S1801